Equivalent VTE Rates After Total Joint Arthroplasty Using Thromboprophylaxis with Aspirin Versus Potent Anticoagulants: Retrospective Analysis of 4562 Cases Across a Diverse Healthcare System

Overview

Journal Arthroplasty

Publisher Biomed Central

Date 2022 Mar 3

PMID 35236505

Authors

Chelsea Matzko

Zachary P Berliner

Gregg Husk

Bushra Mina

Barton Nisonson

Matthew S Hepinstall

Affiliations

Soon will be listed here.

Abstract

Background: Guidelines support aspirin thromboprophylaxis for primary total hip and knee arthroplasty (THA and TKA) but supporting evidence has come from high volume centers and the practice remains controversial.

Methods: We studied 4562 Medicare patients who underwent elective primary THA (1736, 38.1%) or TKA (2826, 61.9%) at 9 diverse hospitals. Thirty-day claims data were combined with data from the health system's electronic medical records to compare rates of venous thromboembolism (VTE) between patients who received prophylaxis with: (1) aspirin alone (47.3%), (2) a single, potent anticoagulant (29%), (3) antiplatelet agents other than aspirin or multiple anticoagulants (21.5%), or (4) low-dose subcutaneous unfractionated heparin or no anticoagulation (2.2%). Sub-analyses separately evaluating THA, TKA and cases from lower volume hospitals (n = 975) were performed.

Results: The 30-day VTE incidence was 0.6% (29/4562). VTE rates were equal in patients receiving aspirin and those receiving a single potent anticoagulant (0.5% in both groups). Patients with VTE were significantly older than patients without VTE (mean 76.5 vs. 73.1 years, P = 0.04). VTE rate did not associate with sex or hospital case volume. On bivariate analysis considering age, aspirin did not associate with greater VTE risk compared to a single potent anticoagulant (OR = 2.1, CI = 0.7-6.3) with the numbers available. Odds of VTE were increased with use of subcutaneous heparin or no anticoagulant (OR = 6.4, CI = 1.2-35.6) and with multiple anticoagulants (OR = 3.6, CI = 1.1-11.2). THA and TKA demonstrated similar rates of VTE (0.5% vs. 0.7%, respectively, P = 0.43). Of 975 cases done at lower volume hospitals, 387 received aspirin, none of whom developed VTE.

Conclusions: This study provides further support for aspirin as an effective form of pharmacological VTE prophylaxis after total joint arthroplasty in the setting of a multi-modal regimen using 30-day outcomes. VTE occurred in 0.7% of primary joint arthroplasties. Aspirin prophylaxis did not associate with greater VTE risk compared to potent anticoagulants in the total population or at lower volume hospitals.

Citing Articles

Low-versus high-dose aspirin for venous thromboembolic prophylaxis after total joint arthroplasty: a systematic review and meta-analysis.

Mirghaderi P, Pahlevan-Fallahy M, Rahimzadeh P, Habibi M, Pourjoula F, Azarboo A J Orthop Surg Res. 2024; 19(1):848.

PMID: 39702480 PMC: 11657554. DOI: 10.1186/s13018-024-05356-w.

Aspirin is Not for Everyone: Discharge to Non-home Facilities After Total Hip and Knee Arthroplasty Increases Risk of Venous Thromboembolism.

McHugh M, Muscatelli S, Squires M, Honey N, Locke C, Dailey E Arthroplast Today. 2024; 27:101368.

PMID: 38577640 PMC: 10990943. DOI: 10.1016/j.artd.2024.101368.

Aspirin is a safe and effective thromboembolic prophylaxis after total knee arthroplasty: a systematic review and meta-analysis.

Za P, Papalia G, Franceschetti E, Rizzello G, Adravanti P, Papalia R Knee Surg Sports Traumatol Arthrosc. 2023; 31(10):4407-4421.

PMID: 37449989 DOI: 10.1007/s00167-023-07500-1.

Comparison of low-dose (162 mg) and high-dose (650 mg) Aspirin prophylaxis following total joint arthroplasty: a prospective cohort study.

Shafiei S, Rastegar M, Mirghaderi P, Siavashi B, Mortazavi S Ann Med Surg (Lond). 2023; 85(5):1461-1467.

PMID: 37229014 PMC: 10205192. DOI: 10.1097/MS9.0000000000000366.

References

Nam D, Nunley R, Johnson S, Keeney J, Clohisy J, Barrack R . Thromboembolism Prophylaxis in Hip Arthroplasty: Routine and High Risk Patients. J Arthroplasty. 2015; 30(12):2299-303. DOI: 10.1016/j.arth.2015.06.045. View

Cote M, Chen A, Jiang Y, Cheng V, Lieberman J . Persistent Pulmonary Embolism Rates Following Total Knee Arthroplasty Even With Prophylactic Anticoagulants. J Arthroplasty. 2017; 32(12):3833-3839. DOI: 10.1016/j.arth.2017.06.041. View

Shah S, Satin A, Mullen J, Merwin S, Goldin M, Sgaglione N . Impact of recent guideline changes on aspirin prescribing after knee arthroplasty. J Orthop Surg Res. 2016; 11(1):123. PMC: 5072339. DOI: 10.1186/s13018-016-0456-0. View

Leali A, Fetto J, Moroz A . Prevention of thromboembolic disease after non-cemented hip arthroplasty. A multimodal approach. Acta Orthop Belg. 2002; 68(2):128-34. View

Raphael I, Tischler E, Huang R, Rothman R, Hozack W, Parvizi J . Aspirin: an alternative for pulmonary embolism prophylaxis after arthroplasty?. Clin Orthop Relat Res. 2013; 472(2):482-8. PMC: 3890197. DOI: 10.1007/s11999-013-3135-z. View

Huang R, Parvizi J, Hozack W, Chen A, Austin M . Aspirin Is as Effective as and Safer Than Warfarin for Patients at Higher Risk of Venous Thromboembolism Undergoing Total Joint Arthroplasty. J Arthroplasty. 2016; 31(9 Suppl):83-6. DOI: 10.1016/j.arth.2016.02.074. View

Johanson N, Lachiewicz P, Lieberman J, Lotke P, Parvizi J, Pellegrini V . Prevention of symptomatic pulmonary embolism in patients undergoing total hip or knee arthroplasty. J Am Acad Orthop Surg. 2009; 17(3):183-96. DOI: 10.5435/00124635-200903000-00007. View

Shohat N, Ludwick L, Goel R, Ledesma J, Streicher S, Parvizi J . Thirty Days of Aspirin for Venous Thromboembolism Prophylaxis Is Adequate Following Total Knee Arthroplasty, Regardless of the Dose Used. J Arthroplasty. 2021; 36(9):3300-3304. DOI: 10.1016/j.arth.2021.05.002. View

Le Manach Y, Collins G, Bhandari M, Bessissow A, Boddaert J, Khiami F . Outcomes After Hip Fracture Surgery Compared With Elective Total Hip Replacement. JAMA. 2015; 314(11):1159-66. DOI: 10.1001/jama.2015.10842. View

10.

Lotke P, PALEVSKY H, Keenan A, Meranze S, STEINBERG M, Ecker M . Aspirin and warfarin for thromboembolic disease after total joint arthroplasty. Clin Orthop Relat Res. 1996; (324):251-8. DOI: 10.1097/00003086-199603000-00031. View

11.

Parvizi J, Huang R, Rezapoor M, Bagheri B, Maltenfort M . Individualized Risk Model for Venous Thromboembolism After Total Joint Arthroplasty. J Arthroplasty. 2016; 31(9 Suppl):180-6. DOI: 10.1016/j.arth.2016.02.077. View

12.

Harris W, Salzman E, Athanasoulis C, Waltman A, DESANCTIS R . Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med. 1977; 297(23):1246-9. DOI: 10.1056/NEJM197712082972302. View

13.

Deitelzweig S, McKean S, Amin A, Brotman D, Jaffer A, Spyropoulos A . Prevention of venous thromboembolism in the orthopedic surgery patient. Cleve Clin J Med. 2008; 75 Suppl 3:S27-36. DOI: 10.3949/ccjm.75.suppl_3.s27. View

14.

Falck-Ytter Y, Francis C, Johanson N, Curley C, Dahl O, Schulman S . Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012; 141(2 Suppl):e278S-e325S. PMC: 3278063. DOI: 10.1378/chest.11-2404. View

15.

McKenna R, Galante J, Bachmann F, Wallace D, Kaushal P, Meredith P . Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J. 1980; 280(6213):514-7. PMC: 1601413. DOI: 10.1136/bmj.280.6213.514. View

16.

. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet. 2000; 355(9212):1295-302. View

17.

Drescher F, Sirovich B, Lee A, Morrison D, Chiang W, Larson R . Aspirin versus anticoagulation for prevention of venous thromboembolism major lower extremity orthopedic surgery: a systematic review and meta-analysis. J Hosp Med. 2014; 9(9):579-85. DOI: 10.1002/jhm.2224. View

18.

Odeh K, Doran J, Yu S, Bolz N, Bosco J, Iorio R . Risk-Stratified Venous Thromboembolism Prophylaxis After Total Joint Arthroplasty: Aspirin and Sequential Pneumatic Compression Devices vs Aggressive Chemoprophylaxis. J Arthroplasty. 2016; 31(9 Suppl):78-82. DOI: 10.1016/j.arth.2016.01.065. View

19.

Schroer W, Diesfeld P, LeMarr A, Morton D, Reedy M . Hip Fracture Does Not Belong in the Elective Arthroplasty Bundle: Presentation, Outcomes, and Service Utilization Differ in Fracture Arthroplasty Care. J Arthroplasty. 2018; 33(7S):S56-S60. DOI: 10.1016/j.arth.2018.02.091. View

20.

Harris W, Salzman E, Athanasoulis C, Waltman A, Baum S, DESANCTIS R . Comparison of warfarin, low-molecular-weight dextran, aspirin, and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. J Bone Joint Surg Am. 1974; 56(8):1552-62. View